These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 31563501)

  • 1. Quality Indicators for Bladder Cancer Services: A Collaborative Review.
    Leow JJ; Catto JWF; Efstathiou JA; Gore JL; Hussein AA; Shariat SF; Smith AB; Weizer AZ; Wirth M; Witjes JA; Trinh QD
    Eur Urol; 2020 Jul; 78(1):43-59. PubMed ID: 31563501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced Quality and Effectiveness of Transurethral Resection of Bladder Tumour in Non-muscle-invasive Bladder Cancer: A Multicentre Real-world Experience from Scotland's Quality Performance Indicators Programme.
    Mariappan P; Johnston A; Padovani L; Clark E; Trail M; Hamid S; Hollins G; Simpson H; Thomas BG; Hasan R; Bhatt J; Ahmad I; Nandwani GM; Mitchell IDC; Hendry D;
    Eur Urol; 2020 Oct; 78(4):520-530. PubMed ID: 32690321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.
    Babjuk M; Burger M; Compérat EM; Gontero P; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Zigeuner R; Capoun O; Cohen D; Escrig JLD; Hernández V; Peyronnet B; Seisen T; Soukup V
    Eur Urol; 2019 Nov; 76(5):639-657. PubMed ID: 31443960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
    Babjuk M; Böhle A; Burger M; Capoun O; Cohen D; Compérat EM; Hernández V; Kaasinen E; Palou J; Rouprêt M; van Rhijn BWG; Shariat SF; Soukup V; Sylvester RJ; Zigeuner R
    Eur Urol; 2017 Mar; 71(3):447-461. PubMed ID: 27324428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection.
    Del Giudice F; Barchetti G; De Berardinis E; Pecoraro M; Salvo V; Simone G; Sciarra A; Leonardo C; Gallucci M; Catalano C; Catto JWF; Panebianco V
    Eur Urol; 2020 Jan; 77(1):101-109. PubMed ID: 31699526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
    Babjuk M; Burger M; Zigeuner R; Shariat SF; van Rhijn BW; Compérat E; Sylvester RJ; Kaasinen E; Böhle A; Palou Redorta J; Rouprêt M;
    Eur Urol; 2013 Oct; 64(4):639-53. PubMed ID: 23827737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ).
    Babjuk M; Burger M; Capoun O; Cohen D; Compérat EM; Dominguez Escrig JL; Gontero P; Liedberg F; Masson-Lecomte A; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Seisen T; Soukup V; Sylvester RJ
    Eur Urol; 2022 Jan; 81(1):75-94. PubMed ID: 34511303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines.
    Alfred Witjes J; Max Bruins H; Carrión A; Cathomas R; Compérat E; Efstathiou JA; Fietkau R; Gakis G; Lorch A; Martini A; Mertens LS; Meijer RP; Milowsky MI; Neuzillet Y; Panebianco V; Redlef J; Rink M; Rouanne M; Thalmann GN; Sæbjørnsen S; Veskimäe E; van der Heijden AG
    Eur Urol; 2024 Jan; 85(1):17-31. PubMed ID: 37858453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance Measurement and Quality Improvement Initiatives for Bladder Cancer Care.
    Ristau BT; Smaldone MC
    Curr Urol Rep; 2018 Oct; 19(12):100. PubMed ID: 30357590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer.
    Leow JJ; Bedke J; Chamie K; Collins JW; Daneshmand S; Grivas P; Heidenreich A; Messing EM; Royce TJ; Sankin AI; Schoenberg MP; Shipley WU; Villers A; Efstathiou JA; Bellmunt J; Stenzl A
    World J Urol; 2019 Jan; 37(1):61-83. PubMed ID: 30684034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.
    Ploussard G; Daneshmand S; Efstathiou JA; Herr HW; James ND; Rödel CM; Shariat SF; Shipley WU; Sternberg CN; Thalmann GN; Kassouf W
    Eur Urol; 2014 Jul; 66(1):120-37. PubMed ID: 24613684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
    Grabe-Heyne K; Henne C; Odeyemi I; Pöhlmann J; Ahmed W; Pollock RF
    J Med Econ; 2023; 26(1):411-421. PubMed ID: 36897006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic therapy issues: Immunotherapy in nonmetastatic urothelial cancer.
    Nadal R; Apolo AB; Girardi DM; Hahn NM; Bellmunt J
    Urol Oncol; 2023 Jan; 41(1):27-34. PubMed ID: 34756410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality indicators for the management of muscle-invasive bladder cancer in the perioperative setting of radical cystectomy: a narrative review.
    König F; Pradere B; Grossmann NC; Quhal F; Rajwa P; Laukhtina E; Mori K; Katayama S; Yanagisawa T; Mostafai H; Motlagh RS; Aydh A; Dahlem R; Shariat SF; Rink M
    Transl Cancer Res; 2022 Apr; 11(4):908-917. PubMed ID: 35571640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines.
    Witjes JA; Bruins HM; Cathomas R; Compérat EM; Cowan NC; Gakis G; Hernández V; Linares Espinós E; Lorch A; Neuzillet Y; Rouanne M; Thalmann GN; Veskimäe E; Ribal MJ; van der Heijden AG
    Eur Urol; 2021 Jan; 79(1):82-104. PubMed ID: 32360052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An International Collaborative Consensus Statement on En Bloc Resection of Bladder Tumour Incorporating Two Systematic Reviews, a Two-round Delphi Survey, and a Consensus Meeting.
    Teoh JY; MacLennan S; Chan VW; Miki J; Lee HY; Chiong E; Lee LS; Wei Y; Yuan Y; Yu CP; Chow WK; Poon DM; Chan R; Lai F; Ng CF; Breda A; Kramer MW; Malavaud B; Mostafid H; Herrmann T; Babjuk M
    Eur Urol; 2020 Oct; 78(4):546-569. PubMed ID: 32389447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis.
    Kamat AM; Lerner SP; O'Donnell M; Georgieva MV; Yang M; Inman BA; Kassouf W; Boorjian SA; Tyson MD; Kulkarni GS; Chang SS; Konety BR; Svatek RS; Balar A; Witjes JA
    Eur Urol Oncol; 2020 Jun; 3(3):318-340. PubMed ID: 32201133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging treatments for bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer.
    Kim HS; Seo HK
    Investig Clin Urol; 2021 Jul; 62(4):361-377. PubMed ID: 34085791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of chronic kidney disease on oncological outcomes in patients with high-risk non-muscle-invasive bladder cancer who underwent adjuvant bacillus Calmette-Guérin therapy.
    Fujita N; Hatakeyama S; Okita K; Momota M; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
    Urol Oncol; 2021 Mar; 39(3):191.e9-191.e16. PubMed ID: 32713622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection and resection of carcinoma in situ of the bladder: Implications for clinical trial design.
    Roumiguié M; Wong A; Belanger E; Wang G; Black PC
    Urol Oncol; 2023 May; 41(5):254.e9-254.e15. PubMed ID: 36566105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.